- Home
- SGN vs XRTX Comparison
SGN vs XRTX Comparison
Compare SGN & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- XRTX
- Stock Information
- Founded
- SGN 2019
- XRTX 2011
- Country
- SGN United States
- XRTX Canada
- Employees
- SGN N/A
- XRTX N/A
- Industry
- SGN
- XRTX Pharmaceuticals and Biotechnology
- Sector
- SGN
- XRTX Health Care
- Exchange
- SGN Nasdaq
- XRTX Nasdaq
- Market Cap
- SGN 3.8M
- XRTX 3.4M
- IPO Year
- SGN 2023
- XRTX N/A
- Fundamental
- Price
- SGN $1.55
- XRTX $0.80
- Analyst Decision
- SGN
- XRTX
- Analyst Count
- SGN 0
- XRTX 0
- Target Price
- SGN N/A
- XRTX N/A
- AVG Volume (30 Days)
- SGN 657.8K
- XRTX 101.0K
- Earning Date
- SGN 08-12-2025
- XRTX 08-26-2025
- Dividend Yield
- SGN N/A
- XRTX N/A
- EPS Growth
- SGN N/A
- XRTX N/A
- EPS
- SGN N/A
- XRTX N/A
- Revenue
- SGN $391,126.00
- XRTX N/A
- Revenue This Year
- SGN N/A
- XRTX N/A
- Revenue Next Year
- SGN N/A
- XRTX N/A
- P/E Ratio
- SGN N/A
- XRTX N/A
- Revenue Growth
- SGN N/A
- XRTX N/A
- 52 Week Low
- SGN $0.44
- XRTX $0.66
- 52 Week High
- SGN $36.70
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- SGN 51.32
- XRTX 46.14
- Support Level
- SGN $1.30
- XRTX $0.73
- Resistance Level
- SGN $1.85
- XRTX $0.93
- Average True Range (ATR)
- SGN 0.20
- XRTX 0.06
- MACD
- SGN 0.01
- XRTX 0.01
- Stochastic Oscillator
- SGN 50.82
- XRTX 51.67
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.